.World Health Institution. Being overweight and also overweight. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (2024 ).
Non-Communicable Illness Danger Element Collaboration. Worldwide fads in skinny as well as being overweight coming from 1990 to 2022: a pooled analysis of 3663 population-representative research studies with 222 million children, youngsters, and also grownups. Lancet 403, 1027u00e2 $ “1050 (2024 ).
Articleu00c2.Google.com Scholaru00c2.Global Problem Condition Partners. Global, local, as well as national concern of diabetes from 1990 to 2021, along with forecasts of occurrence to 2050: a step-by-step evaluation for the Worldwide Problem of Condition Research 2021. Lancet 402, 203u00e2 $ “234 (2023 ).
Articleu00c2.Google.com Scholaru00c2.Kovesdy, C. P., Furth, S. L.
& Zoccali, C & World Renal Day Steering Board. Weight problems and also kidney ailment: hidden repercussions of the epidemic. Renal Int.
91, 260u00e2 $ “262 (2017 ). Garofalo, C. et cetera.
A methodical customer review as well as meta-analysis suggests excessive weight anticipates beginning of chronic renal disease in the overall population. Kidney Int. 91, 1224u00e2 $ “1235 (2017 ).
Articleu00c2.Google Scholaru00c2.Jiang, Z. et al. Weight problems and constant renal ailment.
Am. J. Physiol.
Endocrinol. Metab. 324, E24u00e2 $ “E41 (2023 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Venue, J. E., do Carmo, J. M., da Silva, A.
A., Wang, Z. & Venue, M. E.
Being overweight, renal problems and high blood pressure: mechanistic web links. Nat. Rev.
Nephrol. 15, 367u00e2 $ “385 (2019 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Kidney Illness: Improving Global Results CKD Workplace Group.
KDIGO 2024 Scientific Process Guideline for the examination as well as management of chronic kidney condition. Kidney Int. 105, S117u00e2 $ “S314 (2024 ).
Articleu00c2.Google.com Scholaru00c2.Kidney Condition: Improving Global Outcomes Diabetes Mellitus Work Group. KDIGO 2022 Scientific Practice Suggestion for diabetic issues control in persistent kidney health condition. Kidney Int.
102, S1u00e2 $ “S127 (2022 ). Articleu00c2.Google Scholaru00c2.Oshima, M. et cetera.
Very early change in albuminuria along with canagliflozin predicts renal and cardio outcomes: a message hoc evaluation coming from the support test. J. Am.
Soc. Nephrol. 31, 2925u00e2 $ “2936 (2020 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.de Zeeuw, D. et al. Proteinuria, an intended for renoprotection in people with type 2 diabetic person nephropathy: lessons coming from RENAAL.
Renal Int. 65, 2309u00e2 $ “2320 (2004 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. et al. Is actually a reduction in albuminuria linked with kidney and also cardio security?
A message hoc evaluation of the ALTITUDE test. Diabetes mellitus Obes. Metab.
18, 169u00e2 $ “177 (2016 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Michos, E. D., Bakris, G.
L., Rodbard, H. W. & Tuttle, K.
R. Glucagon-like peptide-1 receptor agonists in diabetic renal illness: a testimonial of their kidney as well as heart defense. Am.
J. Prev. Cardiol.
14, 100502 (2023 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Muskiet, M. H.
A. et cetera. GLP-1 as well as the kidney: from physiology to pharmacology and also results in diabetes.
Nat. Rev. Nephrol.
Thirteen, 605u00e2 $ “628 (2017 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Marso, S. P.
et cetera. Semaglutide as well as cardio end results in individuals with type 2 diabetic issues. N.
Engl. J. Medication.
375, 1834u00e2 $ “1844 (2016 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Lincoff, A. M.
et cetera. Semaglutide and also cardiovascular outcomes in obesity without diabetes. N.
Engl. J. Medication.
389, 2221u00e2 $ “2232 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Perkovic, V. et al.
Effects of semaglutide on constant kidney disease in individuals along with type 2 diabetes. N. Engl.
J. Med. 391, 109u00e2 $ “121 (2024 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Colhoun, H. M. et al.
Lasting kidney outcomes of semaglutide in weight problems as well as heart attack in the SELECT test. Nat. Medication.
30, 2058u00e2 $ “2066 (2024 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Results of semaglutide on albuminuria as well as renal functionality in folks along with over weight or even being overweight along with or even without style 2 diabetic issues: preliminary study from the STEP 1, 2, and also 3 tests.
Diabetes Care 46, 801u00e2 $ “810 (2023 ). Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Medicine Man, A. M.
et al. Effect of the glucagon-like peptide-1 receptor agonists semaglutide as well as liraglutide on kidney results in patients with kind 2 diabetic issues: pooled review of SUSTAIN 6 as well as forerunner. Blood circulation 145, 575u00e2 $ “585 (2022 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Apperloo, E. M. et al.
Effect of semaglutide on renal functionality all over different degrees of baseline HbA1c, high blood pressure, body weight and albuminuria in SUSTAIN 6 and trailblazer 6. Nephrol. Dial.
Transplant. gfae150 (2024 ). Tuttle, K.
R. et al. Dulaglutide versus the hormone insulin glargine in patients along with kind 2 diabetes and also moderate-to-severe severe kidney disease (AWARD-7): a multicentre, open-label, randomised trial.
Lancet Diabetes Endocrinol. 6, 605u00e2 $ “617 (2018 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et al.
Change in albuminuria as a surrogate endpoint for progress of kidney health condition: a meta-analysis of treatment results in randomised clinical tests. Lancet Diabetes Endocrinol. 7, 128u00e2 $ “139 (2019 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Mann, J. F. E.
et cetera. Results of semaglutide along with and also without associated with SGLT2 inhibitor use in attendees with type 2 diabetic issues and also chronic kidney condition in the circulation test. Nat.
Med. https://doi.org/10.1038/s41591-024-03133-0 (2024 ). Neuen, B.
L. et cetera. Cardiovascular, kidney and security outcomes along with GLP-1 receptor agonists alone and in combination with SGLT2 inhibitors in style 2 diabetes: an organized testimonial and also meta-analysis.
Circulation https://doi.org/10.1161/CIRCULATIONAHA.124.071689 (2024 ). Apperloo, E. M.
et cetera. Effectiveness and also protection of SGLT2 preventions along with and also without glucagon-like peptide 1 receptor agonists: a SMART-C collaborative meta-analysis of randomised measured trials. Lancet Diabetes Mellitus Endocrinol.
12, 545u00e2 $ “557 (2024 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et cetera. Impacts of tirzepatide versus blood insulin glargine on kidney results in style 2 diabetes mellitus in the SURPASS-4 test: post-hoc analysis of an open-label, randomised, phase 3 trial.
Lancet Diabetes Mellitus Endocrinol. 10, 774u00e2 $ “785 (2022 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K.
R. et al. Physical body body weight and also eGFR in the course of dulaglutide treatment in kind 2 diabetes mellitus as well as moderate-to-severe persistent renal illness (AWARD-7).
Diabetes mellitus Obes. Metab. 21, 1493u00e2 $ “1497 (2019 ).
Articleu00c2.CASu00c2.Google.com Scholaru00c2.Heerspink, H. J. L.
et cetera. Results of tirzepatide versus the hormone insulin glargine on cystatin c-based kidney functionality: a SURPASS-4 article hoc analysis. Diabetes Treatment 46, 1501u00e2 $ “1506 (2023 ).
Articleu00c2.CASu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Diabetes Care (American Diabetic issues Organization, accessed 1 September 2024) https://diabetesjournals.org/diabetes/issue/73/Supplement_1Li, K. et cetera. Results of bariatric surgery on renal functionality in obese clients: a step-by-step examine and meta study.
PLoS ONE 11, e0163907 (2016 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Bilha, S. C.
et cetera. The results of bariatric surgical operation on kidney end results: a step-by-step analysis as well as meta-analysis. Obes.
Surg. 28, 3815u00e2 $ “3833 (2018 ). Articleu00c2.Google.com Scholaru00c2.Clerte, M.
et cetera. The gauged glomerular filtering cost (mGFR) before and also 6 months after bariatric surgical operation: a captain study. Nephrol.
Ther. 13, 160u00e2 $ “167 (2017 ). Articleu00c2.Google Scholaru00c2.Fawaz, S.
et cetera. Adiponectin lowers glomerular endothelial glycocalyx disturbance as well as repairs glomerular obstacle feature in a mouse model of kind 2 diabetes mellitus. Diabetes mellitus 73, 964u00e2 $ “976 (2024 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Sasson, A. N. & Cherney, D.
Z. Renal hyperfiltration related to diabetic issues mellitus and weight problems in individual disease. Realm J.
Diabetic Issues 3, 1u00e2 $ “6 (2012 ). Articleu00c2.PubMed Centralu00c2.Google Scholaru00c2.Chagnac, A. & Friedman, A.
N. Assessing albuminuria in individuals with being overweight: mistakes of the urinary albumin-creatinine ratio. Renal Med.
6, 100804 (2024 ). Articleu00c2.PubMed Centralu00c2.Google.com Scholaru00c2.Wilding, J. P.
H. et al. Once-weekly semaglutide in grownups along with over weight or excessive weight.
N. Engl. J.
Med. 384, 989u00e2 $ “1002 (2021 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Levey, A.
S. et cetera. A more accurate procedure to estimate glomerular purification percentage from product creatinine: a brand-new prediction equation.
Customization of Diet in Kidney Disease Study Hall. Ann. Intern.
Med. 130, 461u00e2 $ “470 (1999 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Stevens, J.
et cetera. UHPLC-MS/MS strategy for iohexol judgment in individual EDTA and lithium-heparin plasma, individual pee and in goat- and also swine EDTA blood. Bioanalysis 12, 981u00e2 $ “990 (2020 ).
Articleu00c2.CASu00c2.Google Scholaru00c2.Tuttle, K. R. et cetera.
Effectiveness and safety of aldosterone synthase hangup along with and without empagliflozin for constant renal disease: a randomised, regulated, phase 2 test. Lancet 403, 379u00e2 $ “390 (2024 ). Articleu00c2.CASu00c2.Google Scholaru00c2.de Zeeuw, D.
et cetera. Efficiency of an unfamiliar prevention of general adhesion protein-1 in minimizing albuminuria in people along with diabetic kidney illness (CD): a randomised, placebo-controlled, phase 2 trial. Lancet Diabetes Mellitus Endocrinol.
6, 925u00e2 $ “933 (2018 ). Articleu00c2.Google.com Scholaru00c2.Heerspink, H. J.
L. et al. Zibotentan in mix along with dapagliflozin compared to dapagliflozin in clients with severe kidney disease (ZENITH-CKD): a multicentre, randomised, active-controlled, period 2b, clinical trial.
Lancet 402, 2004u00e2 $ “2017 (2023 ). Articleu00c2.CASu00c2.Google Scholaru00c2.Heerspink, H. J.
L. et cetera. Effect of avenciguat on albuminuria in people with CKD: two randomized placebo-controlled tests.
J. Am. Soc.
Nephrol. 25, 1227u00e2 $ “1239 (2024 ). Articleu00c2.Google Scholaru00c2.Heerspink, H.
J. L. et cetera.
Sparsentan in individuals with IgA nephropathy: a prespecified interim review due to a randomised, double-blind, active-controlled scientific test. Lancet 401, 1584u00e2 $ “1594 (2023 ). Articleu00c2.CASu00c2.Google.com Scholaru00c2.